HIV-infection
11
1
1
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
Characteristics of Immunity in Gut Mucosa, Spinal Fluid, Lymph Node and Blood of HIV Negative Thais and Thais With HIV Infection
Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients
Dual Therapy With Boosted Darunavir + Dolutegravir
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance
A Prospective Observational Trial to Determine Cardiovascular Diseases in HIV-infected Patients
Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500
Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens
Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers
Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy